Search
Menu
Home
HTB
2013
July
HTB
July 2013
Contents
Editorial
Volume 14 Number 7/8 July/August 2013
Conference reports
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur
WHO 2013 guidelines: what about the missing formulations?
WHO 2013 guidelines: when the risk:benefit may not favour starting at CD4 count of 500
Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects
Dolutegravir update: drug resistance in people who are treatment-naive and -experienced
Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013
Non-standard combinations: NRTI-sparing combinations
ARVs and bone health: the role of NRTIs in second-line therapy
No viral load rebound off-ART following stem cell transplant: two “cure” cases using reduced intensity conditioning chemotherapy and CCR5 d-32 negative donors
HIV cure research: further capsules at IAS 2013
Partner-dependent immune differences may protect against HIV infection
Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes
5th International Workshop on HIV Pediatrics, 28-29 June 2013, Kuala Lumpur
Vertical transmission continues to decline in UK and Ireland
Decline in late preterm delivery with vaginal birth in Europe
High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+
Decreased growth in ART exposed uninfected infants in Botswana
Antiretrovirals, doses and formulations for children
International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, 4-8 June 2013, Toronto
Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro
Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance
S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir
One in five people with recent HIV infection in Spain have X4/R5 mixed tropic virus
Antiretrovirals
Community request Gilead to study and develop separate formulation of new tenofovir prodrug
Treatment access
Ending global use of d4T: UNITAID to tip market to safer alternatives
TRIPS extension for least developed countries
HIV prevention and transmission
Bangkok Tenofovir Study: US CDC recommends oral PrEP for injecting drug users – based on 16 fewer infections over 5 years
Basic science and immunology
Sad news regarding attempt to duplicate the cure achieved in Timothy Brown
ART reduces HIV reservoirs in elite controllers: implications for cure research
Other news
CROI website: vital community and research resource vanishes
FDA guidance for industry HIV development and trials
On the web
TAG report: Immune system, HIV, and ageing
RITA! summer issue: HIV and cardiovascular disease
PDFs
Volume 14 Number 7/8 July/August 2013 PDF
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
Major update of UK PrEP guidelines online for public consultation
1 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage